<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04174456</url>
  </required_header>
  <id_info>
    <org_study_id>18-215</org_study_id>
    <nct_id>NCT04174456</nct_id>
  </id_info>
  <brief_title>Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy</brief_title>
  <official_title>Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study proceeds with prospective, randomized, open and controlled clinical trials. The&#xD;
      subject of the investigator's study was the first patient diagnosed with dilated&#xD;
      cardiomyopathy. Subjects who agreed to participate in the study and were determined to meet&#xD;
      the selection / exclusion criteria were randomly assigned to each group, and the experimental&#xD;
      group was treated with 20 mg of olmesartan and 5 mg of rosuvastatin for 6 months, and the&#xD;
      control group is treated with 40 mg of valsartan and 5 mg of rosuvastatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myocardial viability plays an important role in improving the function of the heart. To date,&#xD;
      the most reproducible and objective method has been established as a method or tool for&#xD;
      assessing myocardial viability.&#xD;
&#xD;
      Olmesartan is known to have the strongest inhibitory ability of angiotensin receptors&#xD;
      compared with other angiotensin receptor binding inhibitors. Research has been reported that&#xD;
      statin drugs may help improve vascular endothelial function, and several researchers have&#xD;
      suggested that these mechanisms may affect the improvement of myocardial survival. In&#xD;
      addition, studies have shown that angiotensin receptor binding inhibitors and statins may&#xD;
      improve left ventricular function in patients with left ventricular function. However, since&#xD;
      the studies did not assess myocardial survival, the mechanisms could not be clearly&#xD;
      identified.&#xD;
&#xD;
      The purpose of this study is to investigate the effect of olmesartan on myocardial survival&#xD;
      in patients with dilated cardiomyopathy who have left ventricular dysfunction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of glucose metabolism</measure>
    <time_frame>6 month</time_frame>
    <description>data from fludeoxyglucose positron emission tomography</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Olmesartan group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olmesartan 20mg once daily with rosuvastatin 5mg once a day for 6-month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>valsartan 40mg twice daily with rosuvastatin 5mg once a day for 6-month</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FDG PET</intervention_name>
    <description>baseline and 6-month follow-up FDG PET</description>
    <arm_group_label>Olmesartan group</arm_group_label>
    <arm_group_label>Valsartan group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  dilated cardiomyopathy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindication to angiotensin receptor blocker&#xD;
&#xD;
          -  cardiogenic shock&#xD;
&#xD;
          -  sensitive to rosuvastatin&#xD;
&#xD;
          -  liver cirrhosis more than Child class B&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyungil PARK</last_name>
    <role>Study Director</role>
    <affiliation>Dong-A University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyung-Mi Ko</last_name>
    <phone>82-51-240-5740</phone>
    <email>kkmcrc@naver.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Internal Medicine,Dong-A University College of Medicine</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyungil Park, MD</last_name>
      <phone>82-51-240-2733</phone>
      <email>sotier@dau.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Sua Jo, MD</last_name>
      <phone>82-10-3900-9713</phone>
      <email>flysofina@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chang-Bae Sohn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeonghwan Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yong-Seop Kwon, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Su Hong Kim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kyungil Park, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>August 22, 2020</last_update_submitted>
  <last_update_submitted_qc>August 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dong-A University</investigator_affiliation>
    <investigator_full_name>Kyungil Park</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We don't have any plan to make individual participant data (IPD) available to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

